Protein drug targets of Lavandula angustifolia on treatment of rat Alzheimer᾽s disease

Iranian Journal of Pharmaceutical Research

Volumn 14, Issue 1, 2015, Pages 291-302

  Zali, Hakimeh ^a   Zamanian Azodi, Mona ^a   Tavirani, Mostafa Rezaei ^b   Baghban, Alireza Akbar Zadeh ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alzheimer s disease; Drug target; Hippocampus; Lavandula angustifolia; Proteomics

Indexed keywords

ADENOSINE TRIPHOSPHATE 5A1; ALPHA SYNUCLEIN; APOLIPOPROTEIN A1; HEAT SHOCK PROTEIN A5; LAVANDULA ANGUSTIFOLIA EXTRACT; NEUROFILAMENT TRIPLET L PROTEIN; PEPTIDES AND PROTEINS; PEROXIREDOXIN 2; PLANT EXTRACT; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BIOINFORMATICS; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CONTROLLED STUDY; DRUG TARGETING; GENE ONTOLOGY; HIPPOCAMPUS; HISTOPATHOLOGY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEUROPROTECTION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; TWO DIMENSIONAL ELECTROPHORESIS; UPREGULATION;

EID: 84922559840     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Mudher A and Lovestone S. Alzheimer’s disease-do tauists and baptists finally shake hands?. Trends Neurosci. (2002) 25: 22-26.
2. Iqbal K. Tau Pathology in Alzheimer Disease and Other Tauopathies. Biochim. Biophys. Acta (2005) 1739: 198-210.
3. Itzhaki RF and Wozniak MA. Herpes simplex virus type 1 in alzheimer’s disease: the enemy within. J. Alzheimers Dis. (2008) 13: 393-405.
4. Bartzokis G. Alzheimer’s disease as homeostatic responses to age-related myelin breakdown. Neurobiol. Aging (2011) 32: 1341-1371.
5. Bartzokis G, Lu PH and Mintz J. Quantifying age-related myelin breakdown with mri: novel Therapeutic targets for preventing cognitive decline and alzheimer’s disease. J. Alzheimers Dis. (2004) 6: 53-59.
6. Su B, Wang X, Nunomura A, Moreira PI, Lee HG, Perry G, Smith MA and Zhu X., Oxidative Stress Signaling in Alzheimer’s Disease. Curr. Alzheimer Res. (2008) 5: 525-532.
7. Kastenholz B, Garfin DE, Horst J and Nagel KA, Plant Metal Chaperones: A Novel Perspective in Dementia Therapy. Amyloid (2009) 16: 81-83.
8. Wenk GL. Neuropathologic changes in alzheimer’s disease. J. Clin. Psychiatry (2003) 64: 7-10.
9. Braak H and Del Tredici K. Where, when, and in what form does sporadic Alzheimer’s disease begin? Curr.Opin. Neurol. J. (2012) 25: 708-714.
10. Tiraboschi P, Hansen LA, Thal LJ and Corey-Bloom J. The Importance of neuritic plaques and tangles to the development and evolution of AD. Neurol. (2004) 62: 1984-1989.
11. Yankner BA, Duffy LK and Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Sci. (1990) 250: 279-282.
12. Chen X and Yan SD. Mitochondrial abeta: a potential cause of metabolic dysfunction in alzheimer’s disease. IUBMB Life (2006) 58: 686-694.
13. Greig NH. New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha Inhibitors, and GLP-1 receptor agonists. Ann. N. Y. Acad. Sci. (2004) 1035: 290-315.
14. Francis PT, Palmer AM, Snape M and Wilcock GK. The cholinergic hypothesis of alzheimer’s disease: a review of progress. J. Neurol. Neurosurg. Psychiatry (1999) 66: 137-147.
15. Shen ZX. Brain Cholinesterases: II. The molecular and cellular basis of alzheimer’s disease. Med. Hypotheses (2004) 63: 308-321.
16. Akhondzadeh S and Abbasi SH., Herbal medicine in the treatment of Alzheimer’s disease. Am. J. Alzheimers Dis. Other Demen. (2006) 21: 113-118.
17. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL and Furberg CD., Ginkgo biloba for prevention of dementia. J. Am. Med. Assoc. (2008) 300: 2253-2262.
18. Razzaghi-Asl N, Ebadi A, Edraki N, Shahabipour S and Miri R. Fragment-based Binding efficiency indices in bioactive molecular design: a computational approach to bace-1 inhibitors. Iran. J. Pharm. Res. (2013) 3: 423.
19. Ebrahimzadeh MA, Enayatifard R, Khalili M, Ghaffarloo M, Saeedi M and Yazdani Charati J. Correlation between sun protection factor and antioxidant activity, phenol and flavonoid contents of some medicinal plants. Iran. J. Pharm. Res. (2014) 3: 1041-1047.
20. Zali H, RezaeiTavirani M, AziziJalilian F and Khodarahmi R., Proteins expression clustering of Alzheimer disease in rat hippocampus proteome. J. Paramed. Sci. (2013) 4: 111-118.
21. Zamanian- Azodi M, Rezaie-Tavirani M, Heydari-Kashal S, Kalantari S, Dailian S and Zali H. Proteomics analysis of MKN45 cell line before and after treatment with Lavender aqueous extract. Gastroenterol. Hepatol. Bed Bench (2012) 5: 35-42.
22. SoheiliKashani M, RezaeiTavirani M, Salami M and Talaei SA., Aqueous extract of lavender (Lavandulaangustifolia) improves the spatial performance of a rat model of Alzheimer’s disease. Neurosci. Bull. (2011) 27: 99-106.
23. Ghelardini C, Galeotti N, Salvatore G and Mazzanti G. Local anaesthetic activity of the essential oil of avandulaangustifolia. Planta Med. (1999) 65: 700-703.
24. Kovatcheva AG, Koleva II, Ilieva M, Pavlov A, Mincheva M and Konushlieva M. Antioxidant activity of extract from Lavandulavera MM cell cultures. Food Chem. (2001) 72: 295-300.
25. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH and Manji HK. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. (1999) 72: 879-882.
26. Manji HK, McNamara R, Chen G and Lenox RH., Signalling pathways in the brain: Cellular transduction of mood stabilisation in the treatment of manicdepressive illness. Aust. NZJ. Psychiatry (1999) 33: 65-83.
27. Lahiri DK, Farlow MR, Greig NH and Sambamurti K., Current drug targets for alzheimer’s disease treatment. Drug Dev. Res. (2002) 56: 267-281.
28. Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Koleske AJ, Gunther EC, Nygaard HB and Strittmatter SM. Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein. Neuron (2013) 79: 887-902.
29. Selkoe DJ. Alzheimer’s disease: Genes, proteins, and therapy. Physiol. Rev. (2001) 81: 741-766.
30. SoheiliKashani M, Salami M, RezaeiTavirani M and Kafashian MR. Effect of aqueous extract of lavandulaangustifolia on clearance of amyloid beta plaques. JIUMS (2013) 4: 168-175.
31. Paxinos G and Watson C. The Rat Brain in Stereotaxic Coordinates. 6th ed. Academic Press, New York (2007).
32. Zali H, SoheiliKashani M, Vafaee R and Rostaminya L. Expression clustering of proteins of alzheimeric and normal rat hippocampus treated with lavandula angustifolia. JIUMS (2013) 21: 122-135.
33. Nadine D and Metzger S. Fast and sensitive colloidal coomassie G-250 staining for proteins in polyacrylamide gels. J. Vis. Exp. (2009) 30: 1431.
34. Zhou W, Capello M, Fredolini C, Piemonti L, Liotta LA, Novelli F and Petricoin EF., Mass spectrometry analysis of the post-translational modifications of alpha-enolase from pancreatic ductal adenocarcinoma cells. J. Proteome Res. (2010) 9: 2929-2936.
35. Huang W, Sherman BT and Lempicki RA., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. (2009) 4: 44-57.
36. Hashimoto M, Rockenstein E, Crews L and Masliah E. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in alzheimer’s and parkinson’s diseases. Neuromolecular Med. (2003) 4: 21-36.
37. Lacor PN., Aß Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer’s Disease. J. Neurosci. (2007) 27: 796-807.
38. Lauren J. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature (2009) 457: 1128-1132.
39. Hernández F and Avila J., Tauopathies. Cell Mol. Life Sci. (2007) 64: 2219-2233.
40. Zheng W and Wang SY. Antioxidant activity and phenolic compounds in selected herbs. J. Agric. Food Chem. (2001) 49: 5165-5170.
41. Hohmann J, Zupko I, Redei D, Csanyi M, Falkay G, Mathe I and Janicsak G. Protective Effects of the Aerial Parts of Salvia officinalis, Melissa officinalis and Lavandulaangustifolia and their Constituents against Enzyme-Dependent and Enzyme-Independent Lipid Peroxidation. Planta Med. (1999) 65: 576-578.
42. Gilani AH, Aziz N, Khan MA, Shaheen F, Jabeen, Q, Siddiqui BS and Herzig JW. Ethnopharmacological evaluation of the anticonvulsant, sedative and antispasmodic activities of Lavandulastoechas L. J. Ethnopharmacol. (2000) 71: 161-167.
43. Grant SGN and Husi H. Proteomics of multiprotein complexes: answering fundamental questions in neuroscience. Trends Biotechnol. (2001) 19: 49-54.
44. Papadopoulos D, Ewans L, Pham-Dinh D, Knott J and Reynolds R. Upregulation of alpha-synuclein in neurons and glia in inflammatory demyelinating disease. Mol. Cell Neurosci. (2006) 31: 597-612.
45. Alim MA, Hossain MS, Arima K, Takeda K, Izumiyama Y, Nakamura M, Kaji H, Shinoda T, Hisanaga S and Uéda K., Tubulin seeds alpha-synuclein fibril formation. J. Biol. Chem. (2002) 277: 2112-2117.
46. Alim MA, Ma QL, Takeda K, Aizawa T, Matsubara M, Nakamura M, Asada A, Saito T, Kaji H, Yoshii M, Hisanaga S and Uéda K., Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein. J. Alzheimers Dis. (2004) 6: 435-442.
47. Bonini NM and Giasson BI. Snaring the function of alpha-synuclein. Cell (2005) 123: 359-361.
48. Chandra S, Gallardo G, Fernández-Chacón R, Schlüter OM and Südhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell (2005) 123: 383-396.
49. Willingham S, Outeiro TF, DeVit MJ, Lindquist SL and Muchowski PJ. Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Sci. (2003) 302: 1769-1772.
50. Zhu M, Qin ZJ, Hu D, Munishkina LA and Fink AL. Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. Biochem. (2006) 45: 8135-8142.
51. Goedert M., Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. (2001) 2: 492-501.
52. Zhang J, Cai T, Zhao F, Yao T, Chen Y, Liu X, Luo W and Chen J. The Role of α-synuclein and Tau Hyperphosphorylation-Mediated Autophagy and Apoptosis in Lead-induced Learning and Memory Injury. Int. J. Biol. Sci. (2012) 8: 935-944.
53. Salinas M, Wang J, RosadeSagarra M, Martin D, Rojo AI, Martin- Perez J, OrtizdeMontellano PR and Cuadrado A. Protein kinase Akt/PKB phosphorylates hemeoxygenase-1 in-vitro and in-vivo. FEBS Lett. (2004) 578: 90-94.
54. DiDomenico F, Sultana R, Tiu GF, Scheff NN, Perluigi M, Cini C and Butterfield DA. Protein levels of heat shock proteins 27,32,60,70,90 and thioredoxin-1 in amnestic mild cognitive impairment:an investigation on the role of cellular stress response in the progression of Alzheimer disease. Brain Res. (2010) 1333: 72-81.
55. Suh YH and Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer’s disease. Pharmacol. Rev. (2002) 54: 469-525.
56. George JM, Jin H, Woods WS and Clayton DF. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron (1995) 15: 361-372.
57. Moran LB, Kösel S, Spitzer C, Schwaiger FW, Riess O, Kreutzberg GW and Graeber MB., Expression of alpha-synuclein in non-apoptotic, slowly degenerating facial motoneurones. J. Neurocytol. (2001) 30: 515-521.
58. Sun FC, Wei S, Li CW, Chang YS, Chao CC and Lai YK., Localization of GRP78 to mitochondria under the unfolded protein response. Biochem. J. (2006) 15: 31-39.
59. Falahatpisheh H, Nanez A, Montoya-Durango D, Qian Y, Tiffany-Castiglioni E and Ramos KS. Activation profiles of HSPA5 during the glomerular mesangial cell stress response to chemical injury. Cell Stress Chaperones (2007) 12: 209-218.
60. Tsuji T, Shiozaki A, Kohno R, Yoshizato K and Shimohama S. Proteomic profiling and neurodegeneration in Alzheimer’s disease. Neurochem. Res. (2002) 27: 1245-1253.
61. McGraw TS, Mickle JP, Shaw G and Streit WJ., Axonally transported peripheral signals regulate alpha-internexin expression in regenerating motoneurons. J. Neurosci. (2002) 22: 4955-4963.
62. Julien JP and Lariviere J. Functions of intermediate filaments in neuronal development and disease. J. Neurobiol. (2004) 58: 131-148.
63. Cairns NJV, Zhukareva K, Uryu B, Zhang B, Bigio E, Mackenzie IR, Gearing M, Duyckaerts C, Yokoo H, Nakazato Y, Jaros E, Perry RH, Lee VM and Trojanowski JQ., Alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am. J. Pathol. (2004) 164: 2153-2161.
64. Pamplona R, Dalfo E, Ayala V, Bellmunt MJ, Prat J, Ferrer I and Portero-Otín M. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J. Biol. Chem. (2005) 280: 21522-21530.
65. Botia B, Seyer D, Ravni A, Bénard M, Falluel-Morel A, Cosette P, Jouenne T, Fournier A, Vaudry H, Gonzalez BJ and Vaudry D., Peroxiredoxin 2 is involved in the neuroprotective effects of PACAP in cultured cerebellar granule neurons. J. Mol. Neurosci. (2008) 36: 61-72.
66. Hu Y, Malone JP, Fagan AM, Townsend RR and Holtzman DM. Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Mol. Cell Proteomics (2005) 4: 2000-2009.
67. Shi N and Wu MP., Apolipoprotein A-I attenuates renal ischemia/reperfusion injury in rats. J. Biomed. Sci. (2008) 15: 577-583.
68. Castano EM, Roher AE, Esh CL, Kokjohn TA and Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer’s disease and non-demented elderly subjects. Neurol. Res. (2006) 28: 155-163.
69. Videira R, Castanheira P, Grãos M, Salgueiro L, Faro C and Cavaleiro C., A necrodanemonoterpenoid from Lavandulaluisieri essential oil as a cell-permeable inhibitor of BACE-1, the β-secretase in Alzheimer’s disease. Flavour Frag. J. (2013) 28: 380-388.